Featuring an interview with Dr Rana R McKay, including the following topics:

• Prostate Cancer Working Group (PCWG4) revised terminology (0:00)
• Cardiovascular effects associated with GnRH agonists versus antagonists; mechanism of action (2:17)
• Combination therapy using relugolix; factors affecting persistence and adherence to GnRH agents (12:06)
• Takeaways from the Phase III EMBARK study (19:36)
• Use of CAR (chimeric antigen receptor) T-cell therapy and T-cell engagers (27:20)
• Potential role of circulating tumor DNA minimal residual disease testing; use of olaparib/radium-223 (29:24)

CME information and select publications

Featuring perspectives from Dr Alexandra Drakaki, Ms Krisztina Emodi, Dr Terence Friedlander and Ms Margarita Huober, moderated by Dr Friedlander, including the following topics:

• Introduction: Basic Biology of Nonmetastatic Urothelial Bladder Cancer (UBC) (0:00)
• Systemic Therapy for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer (MIBC) (13:35)
• Evolving Approach to Systemic Therapy for Cisplatin-Ineligible Patients with MIBC (37:13)
• Immune Checkpoint Inhibitors in Non-Muscle-Invasive Bladder Cancer (58:55)
• Novel Intravesical Therapies for Nonmetastatic UBC (1:10:20)

NCPD information and select publications

Featuring perspectives from Dr Ashish M Kamat and Prof Thomas Powles, including the following topics:

• Introduction: Life After Radical Cystectomy (0:00)
• Muscle-Invasive Bladder Cancer — Prof Powles (9:15)
• Non-Muscle-Invasive Bladder Cancer — Dr Kamat (37:49)

CME information and select publications

Featuring perspectives from Dr Neeraj Agarwal and Dr Alan H Bryce, including the following topics:

• Introduction (0:00)
• Optimizing the Role of Hormonal Therapy in the Care of Patients with Prostate Cancer — Dr Bryce (2:41)
• Other Available and Emerging Therapeutic Approaches — Dr Agarwal (35:16)

CME information and select publications

Featuring perspectives from Dr Terence Friedlander and Dr Daniel P Petrylak, including the following topics:

• Introduction (0:00)
• Role of Immunotherapeutic Strategies in the Management of Nonmetastatic Urothelial Bladder Cancer (UBC); Emerging Utility of Circulating Tumor DNA Evaluation — Dr Friedlander (3:53)
• Other Novel Agents and Strategies for Nonmetastatic and Metastatic UBC — Dr Petrylak (26:41)

CME information and select publications

Featuring perspectives from Dr Neeraj Agarwal, Dr Elisabeth I Heath, Dr Daniel P Petrylak, Dr Fred Saad and Dr Neal D Shore, moderated by Dr Heath, including the following topics:

• Introduction (0:00)
• Evolving Management of Nonmetastatic Hormone-Sensitive Prostate Cancer (HSPC) — Dr Shore (2:12)
• Current Hormonal Treatment for Metastatic HSPC (mHSPC) — Dr Petrylak (27:54)
• Current and Future Role of PARP Inhibitors for Metastatic Prostate Cancer (mPC) — Dr Agarwal (50:49)
• Emerging Role of AKT Inhibition for Patients with mHSPC — Dr Heath (1:13:12)
• Current and Future Use of Radiopharmaceuticals for mPC — Dr Saad (1:37:26)

CME information and select publications

Dr Thomas Hutson from the Sarah Cannon Research Institute in Abilene, Texas, Dr Eric A Singer from The Ohio State University Comprehensive Cancer Center in Columbus and Dr Ulka Vaishampayan from the University of Michigan Health Rogel Cancer Center in Ann Arbor discuss recent data surrounding the management of localized renal cell carcinoma and share their perspectives on the clinical application.

CME information and select publications

Professor Thomas Powles from Barts Cancer Institute in London, United Kingdom, discusses recent developments with circulating tumor DNA assays in the management of urothelial bladder cancer.

CME information and select publications

Professor Thomas Powles from Barts Cancer Institute in London, United Kingdom, discusses recent developments with circulating tumor DNA assays in the management of urothelial bladder cancer.

CME information and select publications here.

Dr Wassim Abida from Memorial Sloan Kettering Cancer Center in New York, New York, discusses the role of PARP inhibitors in the management of hormone-sensitive and castration-resistant metastatic prostate cancer.

CME information and select publications here.